A Trial of I/V Arniodarone in Paroxysmal Atrial Fibrillation
DOI:
https://doi.org/10.47144/phj.v19i1.357Keywords:
A Trial of I/V Arniodarone in Paroxysmal Atrial FibrillationAbstract
INTRODUCTION:
Aminodarone, a benzofuran compound, originally manufactured in the pharmacologic laboratories in Belgium in 1962 was recognized as a potent coronary dilator in 1967. That Amidarone might have, a new e1ectrophysiologic profile with respect to cardiac muscle was not appreciated until several years later. 3,4,27.
RESULTS:
Fourteen, out of fifteen patients converted to sinus rhythm and there was only one failure that remained in atrial fibrillation and infusion was discontinued after 36 hours of treatment.The rest of nine responders weighing from 45 to 75 Kg. were slow to respond, a compared to the first group.
DISCUSSION:
Amiodarone has been used for almost every arrhythmia (with success), either alone or in combination with other antiarrhythmic agents, and a number of side effects 20,21,22,23,24,25 and drug interactions 16,17,18,19 are known.
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/
